ArticleApplied microbiology and biotechnology2024
Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration.
Article in Applied microbiology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Perfusion development and its potential for cell therapy manufacturing with adherent cells.Applied microbiology and biotechnology · 2026Review
- Spent Medium Inhibits rVSV Infection.Viruses · 2026Article
- Stability of the two enveloped viruses NDV LaSota and YF-ZIKprM/E to support process development.PloS one · 2026Article
- Progress in the research and development of oncolytic virus therapies.Frontiers in pharmacology · 2026Review
- High Cell Density Perfusion Process of Quail Cells Producing Oncolytic rVSV-NDV.Engineering in life sciences · 2025Article
- Navigating the Purification Process: Maintaining the Integrity of Replication-Competent Enveloped Viruses.Vaccines · 2025Review
- Perfusion Process Intensification for Lentivirus Production Using a Novel Scale-Down Model.Biotechnology and bioengineering · 2025Article
- Perfusion process with tangential flow filtration for oncolytic VSV-GP production.Frontiers in bioengineering and biotechnology · 2025Article
- Digital Twin for Continuous Production of Virus-like Particles toward Autonomous Operation.ACS omega · 2024Article
- Repeated harvest enables efficient production of VSV-GP.Frontiers in bioengineering and biotechnology · 2024Article
- Fed-batch strategies for intensified rVSV vector production in high cell density cultures of suspension HEK293 cells.Biotechnology progressArticle
- Harvesting AAV by tangential flow filtration using reverse asymmetric membranes.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell culture-based production of vector-based vaccines and virotherapeutics is of increasing interest. The vectors used not only retain their ability to infect cells but also induce robust immune responses. Using two recombinant vesicular stomatitis virus (rVSV)-based constructs, we performed a proof-of-concept study regarding an integrated closed single-use perfusion system that allows continuous virus harvesting and clarification. Using suspension BHK-21 cells and a fusogenic oncolytic hybrid of vesicular stomatitis virus and Newcastle disease virus (rVSV-NDV), a modified alternating tangential flow device (mATF) or tangential flow depth filtration (TFDF) systems were used for cell retention. As the hollow fibers of the former are characterized by a large internal lumen (0.75 mm; pore size 0.65 μm), membrane blocking by the multi-nucleated syncytia formed during infection could be prevented. However, virus particles were completely retained. In contrast, the TFDF filter unit (lumen 3.15 mm, pore size 2-5 μm) allowed not only to achieve high viable cell concentrations (VCC, 16.4-20.6×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.